lorvotuzumab mertansine
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2009 (NCT00991562)
Timeline
Indications
Mechanism of action
- Neural cell adhesion molecule 1BINDING AGENT
NCAM1 binding agent
Binding to the target tumor cell through NCAM1, the antibody-drug conjugate is internalized and then cleaved inside the cell, leading to localized and enhanced antitumor activity. The conjugated drug DM1 is a synthetic derivative of maytansine, an ansa macrolide that binds to tubulin at the vinca alkaloid-binding site leading to inhibition of microtubule assembly and cell proliferation and to cell death.
- Neural cell adhesion molecule 1INHIBITOR
NCAM1 inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLorvotuzumab mertansine ↗
- ChEMBLCHEMBL1743037 ↗
Also known as
- hun901-dm1, bb-10901
- imgn901
- imgn901
- imgn-901
- lorvotuzumab mertansine
- lorvotuzumab mertansine
- lorvotuzumab mertansine
- lorvotuzumab mertansine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02452554 | Phase 2 | Oct 1, 2015 | National Cancer Institute (NCI) |
| NCT02420873 | Phase 2 | May 12, 2015 | Immunogen, University of Texas at Houston |
| NCT01237678 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | Immunogen |
| NCT00991562 | Phase 1 | Dec 1, 2009 | Immunogen |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunogen | For profit | 3 | 2 | 2 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2015 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2015 |